Market capitalization | $44.31b |
Enterprise Value | $56.08b |
P/E (TTM) P/E ratio | 31.52 |
EV/FCF (TTM) EV/FCF | 30.70 |
EV/Sales (TTM) EV/Sales | 3.70 |
P/S ratio (TTM) P/S ratio | 2.92 |
P/B ratio (TTM) P/B ratio | 6.60 |
Revenue growth (TTM) Revenue growth | 3.45% |
Revenue (TTM) Revenue | $15.16b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
27 Analysts have issued a IQVIA forecast:
27 Analysts have issued a IQVIA forecast:
Jun '24 |
+/-
%
|
||
Revenue | 15,162 15,162 |
3%
3%
|
|
Gross Profit | 4,180 4,180 |
5%
5%
|
|
EBITDA | 3,251 3,251 |
9%
9%
|
EBIT (Operating Income) EBIT | 2,105 2,105 |
12%
12%
|
Net Profit | 1,423 1,423 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Provides biopharmaceutical development services and commercial outsourcing services
Head office | United States |
CEO | Ari Bousbib |
Employees | 87,000 |
Founded | 1950 |
Website | www.iqvia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.